Clinical Trials Logo

Sjogren's Syndrome clinical trials

View clinical trials related to Sjogren's Syndrome.

Filter by:

NCT ID: NCT04035668 Terminated - Sjögren Syndrome Clinical Trials

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

LOUiSSe
Start date: July 12, 2019
Phase: Phase 2
Study type: Interventional

This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome. LOU064 is an oral Bruton's tyrosine kinase (BTK) inhibitor.

NCT ID: NCT03983408 Recruiting - Rheumatic Diseases Clinical Trials

Impact of Korean Red Ginseng on Fatigue in Patients With Rheumatic Disease

Start date: June 17, 2019
Phase: N/A
Study type: Interventional

The objective of a randomized, double-blind, placebo-controlled trial and open-label extension study is to figure out the impact of Korean Red Ginseng (KRG) on fatigue in patients with rheumatic diseases.

NCT ID: NCT03953703 Recruiting - Sjogren's Syndrome Clinical Trials

Levocarnitine for Dry Eye in Sjogren's Syndrome

Start date: November 17, 2021
Phase: Phase 2
Study type: Interventional

This study evaluates the effectiveness of levocarnitine in the treatment of dry eye in adults with Sjogren's syndrome. This will be a crossover study design with all participants receiving both levocarnitine and placebo.

NCT ID: NCT03941184 Completed - Clinical trials for Rheumatoid Arthritis

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

Start date: January 1, 1995
Phase:
Study type: Observational

This case control study aims to determine whether spontaneous coronary artery dissection (SCAD) is associated with autoimmune diseases and to update the incidence of SCAD in a population-based cohort.

NCT ID: NCT03938207 Not yet recruiting - Inflammation Clinical Trials

Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank

Start date: October 1, 2022
Phase:
Study type: Observational

The comprehensive analysis of health records, TCM constitution, biomarker, and whole-genome sequencing among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease in Taiwan: an integrated analysis between Taiwan Biobank and Sjögren's syndrome Database

NCT ID: NCT03937856 Terminated - Clinical trials for Systemic Lupus Erythematosus

Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases

Start date: May 7, 2019
Phase: N/A
Study type: Interventional

This study will assess the effect of a mindfulness meditation program administered via a smartphone application on health-related quality of life for patients with rheumatic disease.

NCT ID: NCT03937271 Withdrawn - Clinical trials for Rheumatoid Arthritis

Objective Measurement Methods for Autoimmune Disease and Dry Eye Syndrome

Start date: April 1, 2019
Phase:
Study type: Observational

To explore the association among TCM pattern, TCM tongue diagnosis and TCM pulse diagnosis for Autoimmune disease and Dry eye syndrome

NCT ID: NCT03935373 Active, not recruiting - Sjögren's Syndrome Clinical Trials

DNA Exome Sequencing TCM for Sjögren's Syndrome

Start date: April 1, 2019
Phase:
Study type: Observational

To explore the association among gene, TCM pattern, TCM tongue diagnosis and TCM pulse diagnosis with the DNA Exome sequencing tools for Sjögren's syndrome

NCT ID: NCT03926286 Completed - Sjogren's Syndrome Clinical Trials

Fecal Microbial Transplant (FMT) for Sjogrens Syndrome

Start date: April 15, 2019
Phase: Phase 1
Study type: Interventional

This is an open label study to evaluate the effect of Fecal Microbiota Transplantation (FMT) on the gut microbiome and Systemic parameters.

NCT ID: NCT03905525 Completed - Sjögren Syndrome Clinical Trials

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

TWINSS
Start date: October 1, 2019
Phase: Phase 2
Study type: Interventional

This study will evaluate safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome.